HomeNDC LookupRxCUI directory › RxCUI 2110455

Pulmonary Hypertension tadalafil 20 MG Oral Tablet [Alyq] — RxCUI 2110455

RxNorm drug concept · Semantic branded drug
RxCUI 2110455 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2110455
Official namePulmonary Hypertension tadalafil 20 MG Oral Tablet [Alyq]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAlyq 20 MG Oral Tablet; Alyq 20 MG Pulmonary Hypertension Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tadalafil: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tadalafil is the active ingredient in several branded products, each approved for a specific use. Cialis (and generic tadalafil tablets) treat erectile dysfunction, an enlarged pro...
  • What exactly is tadalafil used for, and why do I see so many different brand names?
  • It depends on what you're taking it for. For erectile dysfunction, your doctor may prescribe it as-needed — taken before sexual activity — or as a lower once-daily dose so you don'...
  • Do I take it every day, or just when I need it?
📖 Read our full Tadalafil guide →

🕸️ Concept Web — How Pulmonary Hypertension tadalafil 20 MG Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pulmonary Hypertension tadalafil 20 MG Oral Tablet [Alyq] RxCUI 2110455

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tadalafil 358263
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Alyq 2110450
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tadalafil Oral Tablet 402452
    • Tadalafil Oral Product 1160859
    • Tadalafil Pill 1160860
    • Tadalafil Oral Tablet [Alyq] 2110452
    • Alyq Oral Product 2110453
    • Alyq Pill 2110454
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Tadalafil 20 MG [Alyq] SBDC · 2110451
  • Tadalafil Oral Tablet [Alyq] SBDF · 2110452
  • Alyq Oral Product SBDG · 2110453
  • Alyq Pill SBDG · 2110454
  • Alyq BN · 2110450

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2110455 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00480-9277-06 60 TABLET, FILM COATED in 1 BOTTLE (0480-9277-06) ALYQ Teva Pharmaceuticals, Inc. 2024-02-20
Observed labelers: Teva Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.1465
Range $0.1465–$0.1465 · middle 50% $0.1465–$0.1465 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.